Retraction Watch

Early data on potential anti-cancer compound now in human trials was falsified, company admits

A pharmaceutical company has admitted that one of its former researchers falsified early data on a compound that’s designed to fight cancer, now in human trials.

The data, published as an abstract in August 2015 in the journal Cancer Research, reported a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer. The compound, developed by the company Acerta Pharma, has also been the subject of additional trials published in the New England Journal of Medicine and Blood in 2015. The 2015 NEJM study, which had several authors in common with the Cancer Research abstract, showed the agent had “promising safety and efficacy profiles in patients” with relapsed chronic lymphocytic leukemia.

But an investigation into the data underlying the 2015 abstract shows some were falsified, prompting the journal to retract the abstract.

Ed Tucker, senior vice president of Medical Safety, Quality and Compliance at Acerta Pharma, told us that in August 2016 the company identified an issue with the data in the Cancer Research abstract and started an investigation:

Continue reading Early data on potential anti-cancer compound now in human trials was falsified, company admits

Nature adds alert to heavily debated paper about gene editing

Nature has added an “editor’s note” to a high-profile August paper alerting readers to the fact that the article has been subject to criticism.

Journals often flag papers that are being debated — what’s unusual here is that the journal doesn’t label the notice as an official “Expression of Concern,” which are indexed by PubMed. Yet the Nature notice reads just like an expression of concern.

Here’s the text of the new notice, which was added October 2 (and spotted by Paul Knoepfler):

Continue reading Nature adds alert to heavily debated paper about gene editing

Second retraction for psychologist reveals clues about culprit behind misconduct

A social psychologist has retracted a second paper that contains “fabricated or manipulated data.”

The first retraction for William Hart at the University of Alabama — also due to data manipulation — appeared earlier this year. The notice raised some questions over authorship: Hart was the sole author, but he blamed the retraction on a graduate student who supplied the problematic data. The questions continued when Hart’s colleagues posted blogs about the problems that occurred in Hart’s lab, using a pseudonym to describe the student, who apparently admitted to fabricating data.

The author of one of those blogs, Hart’s colleague Alexa Tullett, told us in March that she was retracting another paper she wrote with Hart and the unnamed graduate student. Recently, she confirmed this latest retraction is that paper.

Looking at the author list of the newest retraction, by process of elimination, we now have a lead on the identity of the graduate student who allegedly took responsibility for the misconduct.

Tullett told us:

Continue reading Second retraction for psychologist reveals clues about culprit behind misconduct

Can you spot a fake? New tool aims to help journals identify fake reviews

Fake peer reviews are a problem in academic publishing. A big problem. Many publishers are taking proactive steps to limit the effects, but massive purges of papers tainted by problematic reviews continue to occur; to date, more than 500 papers have been retracted for this reason. In an effort to help, Clarivate Analytics is unveiling a new tool as part of the release of ScholarOne Manuscripts, its peer review and submission software in December, 2017. We spoke to Chris Heid, Head of Product for ScholarOne, about the new pilot program to detect unusual submission and peer review activity that may warrant further investigation by the journal.

Retraction Watch: Fake peer reviews are a major problem in publishing, but many publishers are hyper-aware of it and even making changes to their processes, such as not allowing authors to recommend reviewers. Why do you think the industry needs a tool to help detect fake reviews?

Continue reading Can you spot a fake? New tool aims to help journals identify fake reviews

Co-author of now-retracted paper about video games apparently demoted to “lecturer” by uni

Jodi Whitaker, via University of Arizona

A researcher who co-authored a paper about violent video games that was retracted earlier this year appears to have changed positions, according to her website.

After her PhD was revoked by The Ohio State in August, Jodi Whitaker’s listed position at the University of Arizona changed from “assistant professor” to “lecturer.” The page also has removed the information about her PhD, and lists her highest degree as a master’s degree in social psychology from the University of Michigan.

Whitaker has also removed the retracted paper — which includes the title “Boom, Headshot!” — from her list of publications.

Continue reading Co-author of now-retracted paper about video games apparently demoted to “lecturer” by uni

Errors in govt database prompt authors to retract and replace paper in JAMA journal

Researchers have retracted and replaced a June 2016 paper in JAMA Internal Medicine after discovering errors in their data.

The paper explored whether Accountable Care Organizations (ACOs) — groups of health care providers who earn more when they deliver high-quality care without boosting costs — improve care and lower health care costs for Medicare patients. The paper’s corresponding author, Carrie H. Colla, and her colleagues examined Medicare data over five years and found the ACOs provided “ modest savings on average” and less hospital care.

But the data from the Centers for Medicare & Medicaid Services (CMS) contained errors. According to Colla, after the paper was published, CMS “let us know in the fall [2016] that there were errors in the files, but weren’t able to give us final replacement files until winter.” Continue reading Errors in govt database prompt authors to retract and replace paper in JAMA journal

ORI finds misconduct in case of biologist paid $100K by university to leave

A biologist who studied the impact of diabetes on the eye inappropriately altered data in five images from three papers, according to a new finding of misconduct issued by the U.S. Office of Research Integrity (ORI).

Readers may be familiar with the subject of the findings: Azza El-Remessy, a former tenured associate professor at the University of Georgia (UGA) in Athens, spoke to us earlier this year about her battle with UGA. In June 2016, UGA found her guilty of research misconduct and recommended she be terminated. El-Remessy fought back, hiring a lawyer to contest the findings, and the university ultimately paid her $100,000 to leave. (For more, here’s UGA’s June 2016 investigation report and the settlement agreement between UGA and El-Remessy.) Continue reading ORI finds misconduct in case of biologist paid $100K by university to leave

So, was it plagiarism? Journal retracts three papers over “citation and attribution errors”

When several recent submissions raised a red flag, a pediatrics journal decided to investigate. The journal, Pediatrics in Review, discovered “citation and attribution errors” in three case studies, which the journal has now retracted.

Luann Zanzola, the managing editor of the journal, explained that the editors caught the errors when they scanned the three papers—one published in 2014 and two in 2015—using the plagiarism detection software, iThenticate. Zanzola told us that the three case studies “were flagged for high iThenticate scores,” and when the authors could not adequately explain the amount of text overlap, the editors retracted the papers.

The retraction notices for the three papers, published in the journal’s September 2017 issue, are identical: Continue reading So, was it plagiarism? Journal retracts three papers over “citation and attribution errors”